About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

Medrx Co.,Ltd.(4586) Summary

4586
TSE Growth
Medrx Co.,Ltd.
62
JPY
+3
(+5.08%)
Apr 10, 10:26 am JST
0.42
USD
Apr 9, 9:26 pm EDT
Result
PTS
outside of trading hours
62.2
Apr 10, 10:26 am JST
Summary Chart Historical News Financial Result
PER
PBR
1.39
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 10, 2025
Opening Apr 10, 9:00 am
64 JPY 0.43 USD
Previous Close Apr 9
59 JPY 0.40 USD
High Apr 10, 9:01 am
65 JPY 0.44 USD
Low Apr 10, 9:34 am
62 JPY 0.42 USD
Volume
526,200
Trading Value
0.03B JPY 0.23M USD
VWAP
63.43 JPY 0.43 USD
Minimum Trading Value
6,200 JPY 42 USD
Market Cap
2.94B JPY 0.02B USD
Number of Trades
124
Liquidity & Number of Trades
As of Apr 10, 2025
Liquidity
Mid
1-Year Average
342
1-Year High Jul 16, 2024
3,649
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 4, 2025 0 4,107,300
Mar 28, 2025 0 4,157,600
Mar 21, 2025 0 3,976,900
Mar 14, 2025 0 3,959,700
Mar 7, 2025 0 3,528,600
Company Profile
Medrx Co., Ltd. is a drug discovery venture company with strengths in transdermal drug delivery system technologies and microneedle array technology.
Sector
Pharmaceuticals
Medrx Co., Ltd. aims to create new value-added pharmaceuticals through its proprietary transdermal drug delivery system technologies, primarily ILTS and NCTS. These technologies maximize drug efficacy, reduce side effects, and enable drug administration to patients who have difficulty with oral intake. One of the company's main development pipelines, MRX-5LBT for the treatment of post-herpetic neuralgia, received a Complete Response Letter from the FDA in September 2023. Other pipelines include MRX-4TZT for spastic paralysis, MRX-9FLT for central analgesic, and MRX-7MLL for Alzheimer's disease. Additionally, the company is developing microneedle technology, a vaccine delivery device that allows for painless self-administration. Medrx Co., Ltd. is expanding globally through its U.S. subsidiary and is promoting development and commercialization through partnerships with pharmaceutical companies and other entities.